Dofetilide

Major

Dofetilide Nirogacestat Ogsiveo Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse effects Details Dofetilide Norfloxacin An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Dofetilide Nortriptyline An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Dofetilide Octreotide Bynfezia An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Dofetilide Ofloxacin Floxin® An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Dofetilide Olanzapine An increased risk of QT interval prolongation Details Dofetilide Olodaterol Striverdi An increased risk of QT interval prolongation and an increased risk of ventricular arrhythmias Details Dofetilide Omaveloxolone Skyclarys Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Dofetilide Ondansetron An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Dofetilide Osilodrostat Isturisa Increased risk of QT interval prolongation Details Dofetilide Osimertinib Tagrisso Increased risk of QT interval prolongation Details Dofetilide Oxaliplatin Increased risk of QT-interval prolongation Details Dofetilide Ozanimod Additive effects on heart rate Details Dofetilide Pacritinib Vonjo® Reduced CYP3A4 substrate with NTI exposure, reduced efficacy of CYP3A4 substrate with NTI and an increased risk of QT interval pro... Details Dofetilide Palbociclib Ibrance Increased exposure to CYP3A substrates with a narrow therapeutic index Details Dofetilide Paliperidone Erzofri An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Dofetilide Panobinostat Farydak Increased risk of QT interval prolongation Details Dofetilide Papaverine Pavacot® An increased risk of QT interval prolongation Details Dofetilide Paroxetine Paxil An increased risk of QT interval prolongation Details Dofetilide Pasireotide Signifor Increased risk of QT prolongation Details Dofetilide Pazopanib Votrient Increased dofetilide exposure and an increased risk of QT interval prolongation Details Dofetilide Pentamidine NebuPent An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Dofetilide Perphenazine An increased risk of QT interval prolongation Details Dofetilide Phenobarbital Fidoquel An increased risk of QT interval prolongation, reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Dofetilide Pimavanserin Nuplazid An increased risk of QT interval prolongation Details Dofetilide Pipamperone An increased risk of QT interval prolongation Details Dofetilide Pirtobrutinib Jaypirca Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-related adverse effects Details Dofetilide Pitolisant Wakix Increased risk of QT interval prolongation Details Dofetilide Ponesimod Ponvory Increased risk of bradycardia, an increased risk of QT interval prolongation and torsades de pointes Details Dofetilide Prilocaine An increased risk of cardiotoxicity (decreases in cardiac output, total peripheral resistance and mean arterial pressure) Details Dofetilide Primidone Mysoline An increased risk of QT interval prolongation, reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Dofetilide Probucol An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Dofetilide Procainamide Procan® An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Dofetilide Promethazine Phenadoz An increased risk of QT interval prolongation Details Dofetilide Propafenone Rythmol An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Dofetilide Protriptyline An increased risk of QT interval prolongation Details Dofetilide Quetiapine Seroquel An increased risk of QT interval prolongation Details Dofetilide Quinidine Cardioquin® An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Dofetilide Quizartinib Vanflyta An increased risk of QT interval prolongation Details Dofetilide Ranolazine Aspruzyo Increased CYP3A4 substrate (sensitive or with NTI) exposure and an increased risk of QT interval prolongation Details